Last reviewed · How we verify
NCT06000085
Clinical Performance of a Flowable Giomer Versus a Highly Viscous Glass-ionomer Cement in Restoring Class II Cavities of Primary Molars: A Randomized Clinical Trial
NA trial testing restoration of proximal cavities of primary molars with flowable giomer in Dental Caries Class II in 124 participants. Status unknown.
1 June 2024
Quick facts
| Lead sponsor | Ain Shams University |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 124 |
| Start date | 30 December 2022 |
| Primary completion | 1 June 2024 |
| Estimated completion | 1 June 2024 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- restoration of proximal cavities of primary molars with flowable giomer
- restoration of proximal cavities of primary molars with highly viscous glass ionomer cement
Conditions studied
- Dental Caries Class II — all drugs for Dental Caries Class II →
Sponsor
Ain Shams University
Who can join
Adults 4 to 8, any sex, with Dental Caries Class II. Healthy volunteers can join.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
The clinical performance of Flowable Giomer Beautifil Flow Plus X (Shofu Dental Corporation, Japan) and Glass-hybrid-added HVGIC, Equia Forte (GC Corporation, Tokyo, Japan) in restoring class II cavities of primary molars
Time frame: 12 months
The restorations will be evaluated using the FDI criteria having esthetic, functional, and biological properties
Sponsor's own description
The aim of the present study is to assess Flowable Giomer Beautifil Flow Plus X (Shofu Dental Corporation, Japan) and Glass-hybrid-added HVGIC, Equia Forte (GC Corporation, Tokyo, Japan) in class II cavities of primary molars regarding the following objectives: The primary objective To evaluate and compare the clinical performance of Flowable Giomer Beautifil Flow Plus X (Shofu Dental Corporation, Japan) and Glass-hybrid-added HVGIC, Equia Forte (GC Corporation, Tokyo, Japan) in restoring class II cavities of primary molars after 3,6, and 12 months. The secondary objective To assess the effect of different independent variables on the treatment outcome of the experimental restorative materials. Research question: Is there a difference in the clinical performance between flowable giomers and highly viscous glass ionomer in restoring class II cavities of primary molars? Null Hypothesis There is no difference in the clinical performance between Flowable Giomer Beautifil Flow Plus X (Shofu Dental Corporation, Japan) and Glass-hybrid-added HVGIC, Equia Forte (GC Corporation, Tokyo, Japan) after one year of follow up.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
One-year clinical evaluation of a giomer-based injectable composite compared with a highly viscous glass-ionomer cement in restoring class II cavities of primary molars: a randomized clinical trial.
Ali Eldin SE, Elghazawy RK, Safwat Mustafa D, Khattab NMA. · · 2026 · PMID 42152031 · DOI 10.1186/s12903-026-08509-x
Verify or expand the search:
- PubMed search for NCT06000085
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Dental Caries Class II
Currently open trials in the same condition.
- NCT06563128 — Clinical Success of Single-Color Universal Resin Composites · NA · active not recruiting
- NCT06265116 — One-Step Universal Adhesives: A 3-year Clinical Trial in Class II Composite Restorations · NA · active not recruiting
- NCT06833528 — Clinical Performance of Novel Alkasite Restorative Material "Cention Forte" in Class II Restorations · NA · active not recruiting
Other Ain Shams University trials
Trials by the same sponsor.
- NCT07435493 — Fentanyl Versus Opioid Free Multimodal Analgesia for Perioperative Pain Control in Children With Mild to Moderate Obstru · NA · not yet recruiting
- NCT07482540 — Role of Dexmedatomidine Drug in Prevention of Atrial Fibrillations Post Mitral Valve Surgery · NA · not yet recruiting
- NCT07531030 — Posterior Pericapsular Deep Gluteal Block Combined With Pericapsular Nerve Group and Lateral Femoral Cutaneous Nerve Blo · NA · not yet recruiting
- NCT06839027 — Arterial to Central co2gap in Relation to Outcome After Cardiopulmonary Bypass · not yet recruiting
- NCT07516535 — DISS vs FANS in Suction-Assisted RIRS for Medium-Sized Renal Stones · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06000085 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ain Shams University
- Last refreshed: 8 September 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06000085.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing